Wedbush analyst David Nierengarten initiated coverage of Disc Medicine with an Outperform rating and $30 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRON:
Wedbush analyst David Nierengarten initiated coverage of Disc Medicine with an Outperform rating and $30 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRON: